Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Innovation Pharmaceuticals has reported promising data from ongoing in-vitro testing of its Brilacidin at a US Regional Biocontainment Laboratory (RBL) to treat Covid-19.
Data showed that Brilacidin has a high selectivity index (SI), used to compare the antiviral efficacy between investigational drugs.
In a human lung epithelial cell line, the drug’s SI proved greater than 300, higher than the SIs of a majority of other antiviral drugs tested against Covid-19, said the company.
Innovation Pharmaceuticals CEO Leo Ehrlich said: “Selectivity Index is arguably the most important measure to compare the antiviral efficacy between.